Sars-Cov-2 Spike Glycoprotein S1 Receptor Binding Domain [RBD] (319-541 aa)
SARS-CoV-2 Spike Glycoprotein S1 Receptor Binding Domain [RBD] (319-541 aa)
Référence 32-6269-10
Conditionnement : 10ug
Marque : Abeomics
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
| Amount : | 2 µg |
| Purification : | Protein is >90% pure as determined SDS-PAGE. |
| Content : | CoV-S1 RBD protein is 1mg/ml contains 20mM sodium phosphate (NaPP), 300mM NaCl, pH7.2 |
| Storage condition : | Store at -20°C. |
| AA sequence : | The HEK293 derived recombinant protein contains the Coronavirus 2019 Spike Glycoprotein S1 Receptor Binding Domain [ RBD ], Wuhan-Hu-1 strain, amino acids 319-541 fused to His tag at C-terminal. |
| Alternative Name : | Coronavirus 2019 Spike Glycoprotein-S1 Receptor Binding Domain (319-541 a.a), Recombinant |
Source: HEK293 Cells. A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus.
SARS CoV-2 Spike Glycoprotein S1 RBD was tested for its biological functionality by its binding to recombinant ACE2 receptor protein confirmed by structural complementation reporter assay (NanoBiT®).
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
| There are currently no product reviews |
